Navigation Links
Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
Date:5/7/2009

otal trials, as well as data from the open label extension study.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient's product development candidate, KRYSTEXXA(TM) (pegloticase) for treatment failure gout has reported positive Phase 1, 2 and 3 clinical data. The KRYSTEXXA Phase 3 clinical studies were completed in October 2007; the BLA was filed with the FDA in October 2008 and the FDA granted priority review status in December 2008. The Company submitted amendments to the BLA to the FDA in January 2009 and the FDA extended the review period by three months, revising the PDUFA date to August 1, 2009. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

FORWARD-LOOKING LANGUAGE

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, althou
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
3. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
4. Savient Announces Appointment of David Gionco as Chief Financial Officer
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Savient Submits Biologics License Application (BLA) for pegloticase
8. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. GeoVax Labs, Inc. Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... , May 20, 2013   BioHealth ... focusing on commercializing market-relevant biohealth innovations and increasing ... Maryland , today announced its selection of ... (EIR) for BHI at the National Institutes of ... Institute (NHLBI). Dr. Aiyar will help advance ...
(Date:5/20/2013)... May 20, 2013 Interventional cardiologist Tony ... General Hospital (AGH) Cardiovascular Institute have helped pioneer ... artery disease (CAD) over the past three decades, ... balloon angioplasty and coronary artery stent implantation. , Today, ... play a prominent role in the study of a ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4Kitware Enables Interactive Exploration of CMS Medicare Data 2
... December 3 On,November 28, Essilor cancelled 1,600,000 shares, ... dilutive impact of Oceane bond conversions and,the Company,s stock ... These latest cancellations concerned shares acquired under the 6.9,million ... on July,15, 2008 to offset the dilutive impact of ...
... Dec. 2 Transgenomic,Inc. (OTC Bulletin Board: ... Board: PWRM) today announced that Transgenomic has ... rights for Power3 Medical,s Neurodegenerative,Biomarkers, which include ... disease. Transgenomic plans to offer NuroPro(R) ...
... 2 Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company ... the areas of women,s health and,cancer, announced that Isaac Cohen, Chairman ... at the 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. ... at,the New York Palace Hotel in New York City. , ...
Cached Biology Technology:Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4Bionovo to Present at the Piper Jaffray Healthcare Conference 2
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... in Efficient and Sustainable Global Logistics Operations) is aiming ... the efficiency of intermodal loading systems and the boosting ... 29 European organisations with experience in the logistics sector ... totalling 17,000,000 and a duration of three and a ... develop the semantic components and ontologies shared by the ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... birth to develop the ability to determine sunrise and ... of Chicago shows. The research sheds new light ... behaviors, according to Brian Prendergast, associate professor in psychology ... paper published April 27 in the journal PLoS One. ...
... to investigate such things as how Pacific Northwest forests ... by pests and diseases is being pruned back to ... located in a 500-year-old forest near Stevenson in southwest ... Washington, the Forest Service,s Pacific Northwest Research Station and ...
... An international team of scientists, led by researchers at ... have developed a new method for discerning the functions ... functional networks that reveal how gene products interact to ... in the April 29 issue of the journal Cell. ...
Cached Biology News:From the beginning, the brain knows the difference between night and day 2Era of canopy crane ending; certain research and education activities remain 2Era of canopy crane ending; certain research and education activities remain 3As the worm turns, its secrets are revealed 2
...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
RECK (F-20)...
... polyclonal to Peroxiredoxin 1 Peroxiredoxin ... whose mammalian members have been known ... and apoptosis. Many isoforms (about 50 ... amino acid sequence homology, particularly amino-terminal ...
Biology Products: